MA41645A - Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation - Google Patents
Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisationInfo
- Publication number
- MA41645A MA41645A MA041645A MA41645A MA41645A MA 41645 A MA41645 A MA 41645A MA 041645 A MA041645 A MA 041645A MA 41645 A MA41645 A MA 41645A MA 41645 A MA41645 A MA 41645A
- Authority
- MA
- Morocco
- Prior art keywords
- site
- methods
- genetically engineered
- engineered antibodies
- specific genetically
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562128424P | 2015-03-04 | 2015-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA41645A true MA41645A (fr) | 2018-01-09 |
Family
ID=56848750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA041645A MA41645A (fr) | 2015-03-04 | 2016-03-03 | Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation |
Country Status (10)
Country | Link |
---|---|
US (1) | US20180112004A1 (fr) |
EP (1) | EP3265133A1 (fr) |
JP (1) | JP2018511579A (fr) |
CN (1) | CN107530443A (fr) |
AU (1) | AU2016226042A1 (fr) |
BR (1) | BR112017018940A2 (fr) |
CA (1) | CA2978630A1 (fr) |
MA (1) | MA41645A (fr) |
MX (1) | MX2017011344A (fr) |
WO (1) | WO2016141285A1 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201405130UA (en) * | 2012-02-24 | 2014-11-27 | Stemcentrx Inc | Anti sez6 antibodies and methods of use |
CN107207582A (zh) * | 2015-02-16 | 2017-09-26 | 隆萨有限公司 | 用于药物缀合的cl和/或ch1突变抗体 |
CA2988806A1 (fr) | 2015-06-29 | 2017-01-05 | Immunogen, Inc. | Conjugues d'anticorps a cysteine modifiee |
EP3544983A2 (fr) | 2016-11-23 | 2019-10-02 | Immunogen, Inc. | Sulfonation sélective de dérivés de benzodiazépine |
WO2019178539A1 (fr) * | 2018-03-16 | 2019-09-19 | Ngm Biopharmaceuticals, Inc. | Anticorps bispécifiques |
PE20211497A1 (es) * | 2018-05-30 | 2021-08-11 | Abbvie Stemcentrx Llc | Conjugados de farmaco y anticuerpo anti-sez6 y metodos de uso |
EP4106819A1 (fr) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Conjugués d'anticorps de nectine-4 et leurs utilisations |
WO2022152289A1 (fr) * | 2021-01-18 | 2022-07-21 | Wuxi Biologics (Shanghai) Co., Ltd. | Anticorps modifié et conjugués anticorps-médicament le comprenant |
CN117164701A (zh) * | 2022-12-27 | 2023-12-05 | 优洛生物(上海)有限公司 | 一种经改造的抗体、其制备方法及其用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1791565T3 (en) * | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
CA2614082A1 (fr) * | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | Compositions et methodes de desagregation des proteines |
US9968687B2 (en) * | 2013-02-22 | 2018-05-15 | Abbvie Stemcentrx Llc | Anti-DLL3 antibody drug conjugates |
SG11201601375VA (en) * | 2013-08-28 | 2016-03-30 | Stemcentrx Inc | Engineered anti-dll3 conjugates and methods of use |
-
2016
- 2016-03-03 MA MA041645A patent/MA41645A/fr unknown
- 2016-03-04 CA CA2978630A patent/CA2978630A1/fr not_active Abandoned
- 2016-03-04 CN CN201680026026.0A patent/CN107530443A/zh active Pending
- 2016-03-04 AU AU2016226042A patent/AU2016226042A1/en not_active Abandoned
- 2016-03-04 US US15/555,368 patent/US20180112004A1/en not_active Abandoned
- 2016-03-04 JP JP2017546206A patent/JP2018511579A/ja active Pending
- 2016-03-04 WO PCT/US2016/020876 patent/WO2016141285A1/fr active Application Filing
- 2016-03-04 MX MX2017011344A patent/MX2017011344A/es unknown
- 2016-03-04 BR BR112017018940A patent/BR112017018940A2/pt not_active Application Discontinuation
- 2016-03-04 EP EP16759572.7A patent/EP3265133A1/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2016141285A1 (fr) | 2016-09-09 |
US20180112004A1 (en) | 2018-04-26 |
BR112017018940A2 (pt) | 2018-04-17 |
AU2016226042A1 (en) | 2017-09-21 |
CN107530443A (zh) | 2018-01-02 |
CA2978630A1 (fr) | 2016-09-09 |
EP3265133A1 (fr) | 2018-01-10 |
MX2017011344A (es) | 2018-04-13 |
JP2018511579A (ja) | 2018-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41645A (fr) | Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation | |
MA48579A (fr) | Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci | |
MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
MA45123A (fr) | Anticorps anti-tim-3 et leurs méthodes d'utilisation | |
MA50957A (fr) | Anticorps anti-tigit et leurs méthodes d'utilisation | |
MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
MA50359A (fr) | Anticorps anti-cd38 et procédés d'utilisation | |
MA43387A (fr) | Anticorps anti-gitr et leurs méthodes d'utilisation | |
FR22C1048I2 (fr) | Anticorps anti-cd3 et méthodes d'utilisation | |
MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
MA42971A (fr) | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation | |
MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
MA42446A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation | |
MA42447A (fr) | Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA44776A (fr) | Anticorps anti-vista humain et leur utilisation | |
MA45671A (fr) | Anticorps antivirus zika et procédés d'utilisation | |
MA44723A (fr) | Anticorps agonistes se liant au cd40 humain et leurs utilisations | |
MA42243A (fr) | Anticorps de facteur xi et méthodes d'utilisation | |
MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
MA44081A (fr) | Anticorps anti-c5 et leurs procédés d'utilisation |